Needham maintains Alcon at Buy, keeps price target at $98

Alcon acquired Neurotech Pharmaceuticals for $550M, gaining FDA-approved MacTel eye therapy ENCELTO. The deal includes a cell-therapy platform for potential future treatments. Alcon expects modest sales growth in 2027, with slight EPS dilution initially. The company reported $5.5B in first-half 2026 net sales, up 9% YoY, with Surgical segment sales also rising 9%.

Alcon acquires Neurotech for $550M to bolster its retina portfolio. Encelto, a therapy for rare eye disease MacTel, was FDA-approved in March 2025. Alcon aims to expand access to this treatment, which had no prior approved options. Neurotech's CEO highlights Alcon's global scale and expertise in facilitating patient access.

Alcon, a Swiss eye care company, acquired privately held Neurotech Pharmaceuticals for $550M, potentially adding more contingent payments. The deal includes Encelto, an encapsulated cell therapy expected to be approved in 2025, according to Alcon. The acquisition aims to expand Alcon's therapeutic portfolio.

Alcon (SIX/NYSE:ALC) acquired Neurotech Pharmaceuticals for $550M, adding ENCELTO, a treatment for MacTel, to its retina portfolio. The FDA-approved therapy is expected to be modestly accretive to sales growth in 2027. Alcon anticipates slight dilution to EPS initially, with accretion expected later.

Alcon (ALC) acquired Neurotech Pharmaceuticals for $550M, gaining ENCELTO, the only FDA-approved treatment for adult MacTel Type 2. Alcon expects modest sales growth and slight EPS dilution in 2027, with accretion thereafter, according to the company.

Alcon acquires Neurotech and ENCELTO, the only FDA-approved treatment for MacTel Type 2, a rare retinal disease. The deal expands Alcon's retina portfolio and is expected to be modestly accretive to net sales growth from 2027. ENCELTO is a surgical cell therapy for MacTel, with around 25,000 diagnosed patients in the US. Neurotech is a private biotech company.